<DOC>
	<DOCNO>NCT02396238</DOCNO>
	<brief_summary>The primary objective study assess safety efficacy Celution Device process autologous graft consist adipose derive regenerative cell ( ADRCs ) treatment hand dysfunction due scleroderma .</brief_summary>
	<brief_title>Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells ( STAR )</brief_title>
	<detailed_description>The STAR Trial prospective , randomize , multi-center device trial intend assess safety efficacy subcutaneous administration Celution process ADRCs finger patient hand dysfunction due scleroderma . Following informed consent screen evaluation , eligible subject undergo pre-operative testing . Subjects undergo fat harvest small volume liposuction local anesthesia . Lipoaspirate process Celution System isolate concentrate ADRCs immediate subcutaneous administration local anesthesia . Subjects randomly assign receive ADRCs ( 40 million cell ) visually-matched placebo 1:1 ratio . All subject receive subcutaneous administration test substance ( ADRC placebo ) finger hand . Following completion 48 week visit database lock , placebo treat subject offer treatment ADRCs cell continue qualify accord inclusion/exclusion criterion wish treat ADRCs agree fat harvest procedure .</detailed_description>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Raynaud Disease</mesh_term>
	<criteria>Key 1 . Males females ≥ 18 ≤ 70 year age 2 . Diagnosis diffuse cutaneous scleroderma ( duration &gt; 5 year ) limit cutaneous scleroderma . 3 . Cochin score ≥ 20 unit 4 . Ability safely undergo liposuction 5 . Symptoms consistent Raynaud 's Phemomena 6 . Compliant standard preventative recommendation Key 1 . Body Mass Index &lt; 18 kg/m2 2 . Active infection finger screen period infection finger require antibiotic 30 day prior Screening Visit 3 . Active infection potential site ( ) fat harvest screen period 4 . Contractures finger ulceration point injection preclude completion injection procedure 5 . Amputation finger proximal proximal interphalangeal joint amputation one finger 6 . Diagnosis Rheumatoid Arthritis 7 . Inflammatory arthritis hand , include significant osteoarthritis , due scleroderma significant acute inflammation hand due scleroderma , per investigator 's clinical judgment 8 . Oral cyclophosphamide exceed 2 mg/kg/day , intravenous cyclophosphamide , methotrexate exceed 25 mg/week , mycophenolate mofetil exceed 3 gm/day , hydoxychloroquine exceed 7 mg/kg/day azathioprine exceed 300 mg/day immunosuppressive medication 90 day prior Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>